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Abstract
Background: In cardiopulmonary bypass (CPB) patients, fibrinolysis may enhance postoperative inflammatory
response. We aimed to determine whether an additional postoperative dose of antifibrinolytic tranexamic acid (TA)
reduced CPB-mediated inflammatory response (IR).
Methods: We performed a randomized, double-blind, dose-dependent, parallel-groups study of elective CPB
patients receiving TA. Patients were randomly assigned to either the single-dose group (40 mg/Kg TA before CPB
and placebo after CPB) or the double-dose group (40 mg/Kg TA before and after CPB).
Results: 160 patients were included, 80 in each group. The incident rate of IR was significantly lower in the double-
dose-group TA2 (7.5% vs. 18.8% in the single-dose group TA1; P = 0.030). After adjusting for hypertension, total
protamine dose and temperature after CPB, TA2 showed a lower risk of IR compared with TA1 [OR: 0.29 (95% CI: 0.10-
0.83), (P = 0.013)]. Relative risk for IR was 2.5 for TA1 (95% CI: 1.02 to 6.12). The double-dose group had significantly
lower chest tube bleeding at 24 hours [671 (95% CI 549-793 vs. 826 (95% CI 704-949) mL; P = 0.01 corrected-P
significant] and lower D-dimer levels at 24 hours [489 (95% CI 437-540) vs. 621(95% CI: 563-679) ng/mL; P =0 . 0 1
corrected-P significant]. TA2 required lower levels of norepinephrine at 24 h [0.06 (95% CI: 0.03-0.09) vs. 0.20(95 CI: 0.05-
0.35) after adjusting for dobutamine [F = 6.6; P = 0.014 corrected-P significant].
We found a significant direct relationship between IL-6 and temperature (rho = 0.26; P < 0.01), D-dimer (rho = 0.24; P <
0.01), norepinephrine (rho = 0.33; P < 0.01), troponin I (rho = 0.37; P < 0.01), Creatine-Kinase (rho = 0.37; P < 0.01), Creatine
Kinase-MB (rho = 0.33; P < 0.01) and lactic acid (rho = 0.46; P < 0.01) at ICU arrival. Two patients (1.3%) had seizure, 3
patients (1.9%) had stroke, 14 (8.8%) had acute kidney failure, 7 (4.4%) needed dialysis, 3 (1.9%) suffered myocardial
infarction and 9 (5.6%) patients died. We found no significant differences between groups regarding these events.
Conclusions: Prolonged inhibition of fibrinolysis, using an additional postoperative dose of tranexamic acid reduces
inflammatory response and postoperative bleeding (but not transfusion requirements) in CPB patients. A question
which remains unanswered is whether the dose used was ideal in terms of safety, but not in terms of effectiveness.
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Excessive bleeding and inflammatory response (IR) after
cardiopulmonary bypass (CPB) are common complica-
tions of cardiac surgery [1]. Although tranexamic acid
(TA), a lysine analog competitive inhibitor of plasmin
and plasminogen [2], is effective in reducing bleeding
after cardiac surgery, its anti-inflammatory effect in
fibrinolysis blockade has been less studied.
In vitro studies suggest that the exposure of D-dimer
fragments to monocytes initiates the synthesis and release
of IL-6 [3]. Excessive plasmin activity and/or D-dimer for-
mation may play an important role in proinflammatory
cytokine and cellular response activation during CPB [4].
In patients undergoing elective CPB, prophylactic blockade
of fibrinolysis decreases molecular expression of IR [5].
This IR may contribute to postoperative complications,
including myocardial dysfunction, respiratory failure, renal
and neurologic dysfunction, bleeding disorders, altered
liver function, and ultimately, multiple organ failure
(MOF) [4]. In a previous study using TA before and after
CPB we observed reduced bleeding and IR [6]. These
results were encouraging but left unanswered the question
of whether the postoperative dose, coinciding with greatest
fibrinolytic activation, was determinant in decreasing post-
operative IR and bleeding. Nevertheless newer data indi-
cate that, in a dose-dependent fashion, TA is associated
with an increase of adverse events, particularly the obser-
vation of seizures [7]. The incidence of this adverse effect
varies from 2.7% to 4.6% in any major surgical procedure,
independently of dosing schedule [8-10]. For this reason,
we also focused on the safety profile of TA dosing sche-
dule as a part of the study.
Methods
The study was approved by our university hospital ethics
committee and conducted according to the Helsinki
Declaration. We report this trial in accordance with the
CONSORT statement revised recommendations [11].
From December 2005 to January 2007, we performed a
randomized, double-blind, dose-dependent parallel-groups
study with 160 consecutive adult patients undergoing elec-
tive CPB, in a 24-bed intensive care unit (ICU) at a univer-
sity hospital.
Exclusion criteria included: no informed consent, age <
18 years, emergencies, off-pump cardiac surgery, chronic
coagulopathy (prothrombin time [PT] <50% or interna-
tional normalized ratio (INR) >2 and platelets <50,000/
mm
3 or aggregation dysfunction), renal failure (creatinine
>2 mg/dL), gross hematuria, TA hypersensibility, chronic
hepatopathy (Child-B or higher), immunosuppression,
endocarditis and post-operative sepsis within 24 h.
Before CPB, all participants had normal bleeding time,
platelet collagen/epinephrine and collagen/ADP closure
time, PT, activated partial thromboplastin time, and
thrombin time. No patients received anti-inflammatory
or immunosuppressive agents during 5 days before and
24 h post-CPB.
After obtaining written informed consent, the surgeon
requested treatment group assignment immediately
before CPB.
TA dosing schedule
Dosing schedules for prophylactic TA varies greatly
[12,13]. In our center, the TA dosing schedule is an initial
bolus (25 mg/Kg) before CPB and another (25 mg/Kg)
after completion of CPB. Our first study dealing with TA
versus placebo was carried out using this schedule, which
has demonstrated its effectiveness in relation to bleeding
and IR [6]. Given the half-life of TA (80 min), the initial
dose inhibits intra-operative fibrinolysis and bleeding. A
loading dose higher than 30 mg/Kg assures a 98-100%
reduction of tissue activator activity [14]. Thus the dose
schedule used in our study ensured complete inhibition
of fibrinolysis during and early postoperative period after
CPB, although no pharmacokinetic information was
available. With the second dose we wished to investigate
the possible benefit of postoperative inhibition of fibrino-
lysis on IR.
The patients were randomly assigned, by an independent
pharmacist according to a computer generated randomiza-
tion list allocated in the Pharmacology Department, to
receive disguised coded infusions of either TA 40 mg/Kg
before CPB and placebo after CPB (TA1) or TA 40 mg/Kg
before and after CPB (TA2) after heparin reversal. The
code was revealed once recruitment, data collection, and
laboratory analyses were completed.
Anesthetic procedures
Anesthetic procedures were standardized and consisted of
an opioid-based anesthetic supplemented with volatile
anesthetic and muscle relaxants. All interventions were
performed by the same surgical team with wide experience
in these surgical interventions. All patients were preopera-
tively monitored with a pulmonary artery continuous ther-
modilution catheter (Edwards Lifesciences LLC, Irvine,
CA, USA). Neither heparin-coated circuits nor leukocyte
filters were used. The extracorporeal circuit consisted of a
hardshell membrane oxygenator (Optima XP; Cobe, Den-
ver, CO, USA, or Quantum Lifestream International, Inc.,
Woodlands, TX, USA), a Tygon™ (Dideco s.r.l., Miran-
dola, Italy) extracorporeal circuit, and a Medtronic™ Bio-
pump (Medtronic, Inc., Minneapolis, MN, USA)
centrifugal pump. Below hypothermic temperatures of
28°C to 30°C, the pump flow was adjusted to maintain a
mean arterial pressure of greater than 60 mm Hg and a
flow index of 2.2 L/minute per square meter. Myocardial
protection was achieved using antegrade, cold, St. Thomas
4:1 sanguineous cardioplegia. The circuit was primed with
Jiménez et al. Journal of Cardiothoracic Surgery 2011, 6:138
http://www.cardiothoracicsurgery.org/content/6/1/138
Page 2 of 1030 mg of heparin followed by an initial dose of 3 mg/kg
and further doses when necessary to achieve and maintain
an activated clotting time of 480 seconds. To reverse the
effect of heparin, protamine was used based on blood
heparin levels measured by Hepcon
® (Medtronic, Inc.). A
blood salvage device (Cobe BRAT2™, Cobe Cardiovascu-
lar Inc.TX. USA) was used in all patients. The transfusion
trigger was a hemoglobin threshold of less than 8 g/dL, PT
of less than 50%, and platelets of less than 50,000/mm3.
Fluid management was carried out to achieve 8 to 12 mm
Hg of central venous pressure or 12 to 15 mm Hg of
pulmonary artery occlusion pressure at zero positive end-
expiratory pressure by infusions of crystalloids and col-
loids. Following our routine practice, we used Ringer
Lactate or Saline 0.9% in the intra-operative period. After
patient admission to ICU, crystalloids were mainly used
and when colloids were infused we most commonly used
HES 130/0.4 (Voluven
®), not exceeding 1000 ml in
24hours.
Catecholamine support, when necessary, was used as
follows: Norepinephrine was titrated to achieve a mean
arterial pressure of greater or equal to 70 mm Hg, and
dobutamine was titrated to achieve a cardiac index of
greater or equal to2.5 L/minute per square meter.
Amines were tapered off in steps of 0.02 and 1 μg/kg
per minute, respectively.
Concurrent validation
We validated the clinical criteria of IR and found signifi-
cant differences in evolutionary levels of IL-6 in patients
who developed IR versus those without.
Data collection
Demographic variables, comorbidity, perioperative clinical
data, and postoperative IR, mechanical ventilation time,
ICU and hospital stay, and mortality, were recorded. Core
body temperature, laboratory data (hematology, inflamma-
tion, coagulation, and fibrinolysis), and hemodynamic
parameters were recorded before intervention (baseline),
on ICU admission after surgery (0 h), and at 4 h and 24 h
post-CPB, once hemodynamic stability was confirmed. IR
was clinically defined as core body temperature >38°C
(100.4°F), systemic vascular resistance index <1,600 dyne ·
sec/cm
5 per m
2, and cardiac index >3.5 L/minute per m
2
a t4h ,a sw er e p o r t e di nap r e v i o u ss t u d y[ 6 ] .W ea l s o
recorded blood loss (chest-tube drainage and hemoderiva-
tives) at the above time points and on chest tubes removal.
In cases of reintervention due to bleeding, the post-hoc
classification of bleeding into “surgical” and “non-surgical”
was applied to distinguish between bleeding due to
mechanical-surgical causes (where pharmacological mea-
sures are not effective) and coagulopathy (which TA was
expected to reduce). Surgical risk was calculated by Euro-
score and Parsonnet score.
Cerebrovascular events included seizure and stroke.
Acute kidney injury was assessed applying RIFLE [15] cri-
teria (>100% creatinine increase, using preoperative and
highest creatinine concentration during the first week
after surgery); renal failure was defined as dysfunction
requiring dialysis. Myocardial infarction was considered as
either new Q waves or new, persistent ST-segment or T-
wave changes. Indication for re-operation was determined
by clinical judgment and blood loss as >200 mL/h in three
consecutive hours. Mortality was defined as death within
30 days of CPB, recorded in medical history or telephone
contact with the surgeon responsible or family. These
adverse effects were included as a composite variable.
Cytokine levels
IL-6 (normal range: <5.9 pg/mL; intra-assay variation:
4.5%) was measured by automatic immunoenzyme assay
(IMMULITE ONE™; Diagnostic Products Corporation).
Coagulation and fibrinolysis determination
D-dimer (normal range: < 300 ng/mL; intra-assay varia-
tion: 3%) was measured by immunoturbidimetric test
(D-dimer PLUS; Dade Behring).
Statistical analysis
Sample size
In relation to the power of the study, prior experimental
information available is as follows: the proportion of IR in
patients receiving 30 mg/kg in two doses was 16.6% [6];
however, we had no prior information on the expected
incidence rate of IR with 80 mg/kg. In the present study,
we hypothesized that the double dose of TA would reduce
the inflammatory response. For expected incidences of
16.6% in the TA1 group (40-0 mg/Kg) and 3% in the TA2
group, with 80% power and 5% type one error (one-tailed),
58 patients per group were needed. Assuming 28% drop-
out, 80 patients were required in each treatment group.
For the concurrent validation of the clinical criteria of
IR, we used mixed ANOVA with repeated measures of
evolutionary levels of IL-6 (baseline, at ICU arrival, and
at 4 h postoperatively), after log-transformation. The
intergroup variable was IR (yes or no). After applying
the Bonferroni correction, differences with a p value of
<0.018 were considered significant.
Comparisons between groups (TA1 versus TA2) were
performed per protocol analyses, using Pearson’s c
2 test
or Fischer’s exact test for categorical variables, and Stu-
dent’s t-test or Mann-Whitney’s U test for continuous
variables. Assumption of normality of the TA groups was
tested with the Kolmogorov-Smirnov test, and homosce-
dasticity was tested with the Levene test. When any
adjustment or multiple comparisons were necessary on
applying analysis of covariance or mixed ANOVA, the
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mal distribution and homoscedasticity.
All preoperative variables showing a P value < 0.15 in
the bivariate analysis (hypertension, post-CPB tempera-
ture, total protamine dose) were entered in a multivari-
ate binary logistic regression analysis, for categorical
primary end-point outcome (IR).
Mixed ANOVA was used to compare means between
groups in clinical signs (bleeding) and laboratory para-
meters (D-dimer, creatine kinase and troponin I) at base-
line, 4 h and 24 h after surgery. For bleeding and D-dimer,
correction for multiple variables was not carried out in the
omnibus test because of the a priori known unidirectional
nature of the effects of TA on these parameters. However,
any isolated values in repeated measures were considered
significant when P < 0.018, after applying Bonferroni cor-
rection. In the case of 24 h bleeding, this was adjusted for
surgery-related bleeding.
To test the effect of TA on 24 h postoperative norepi-
nephrine requirements, the statistical analysis included
adjustment for the use of dobutamine. After applying
Bonferroni correction, differences with a P value of <
0.018 were considered significant.
Bivariate associations between IL-6 and D-dimer,
chest-tube bleeding, norepinephrine dose, temperature,
troponin I (TnI), creatine kinase (CK), MB isoenzyme
creatine kinase (CK-MB) and blood pressure were
assessed using Spearman’s rho coefficient.
Qualitative variables are expressed as frequencies and
percentages and quantitative variables as mean and 95%
confidence interval (CI), or median and interquartile
range. P values of < 0.05 were considered significant.
SPSS 15.0.1 (SPSS Inc. Chicago, IL. USA) and Statistica
8.0 (StatSoft, Tulsa, OK) were used.
Results
From December 2005 to January 2007, we recruited 209
consecutive CPB patients; 49 were excluded (20 off-pump,
4 coagulation disorders, 11 emergencies, 6 endocarditis, 4
hemodialysis, and 4 immunosuppressed). Thus we studied
160 patients, 80 receiving single-dose TA before CPB and
80 receiving TA before and after CPB. Figure 1 shows a
flow chart of patients enrolled.
Demographic variables, comorbidity, medical treat-
ment, preoperative biochemical data, and surgical proce-
dures were similar in the two groups, except for post-
CPB temperature and total protamine dose (Table 1).
Patients developing IR showed significantly higher
levels of IL-6 at 4 hours postoperatively than those with-
out IR, [F (2, 274) = 5.08; P = 0.013], (Figure 2).
The incident rate of IR was significantly lower in TA2
(7.5%) than in TA1 (18.8%) (P = 0.030). TA2 showed OR
0.29 (95%CI: 0.10-0.83), (P =0 . 0 1 3 )a f t e ra d j u s t i n gf o r
hypertension, total protamine dose and temperature after
CPB. Compared with TA2, the relative risk of IR was 2.5
for TA1 (95% CI 1.02-6.12). The absolute risk difference
was 11.3%. The number needed to treat with TA2 to
reduce IR was 9 patients (95% CI: 5-107 patients).
In the omnibus test TA2 had significantly lower chest-
tube bleeding (P = 0.014). Comparing both groups for
chest bleeding at 24 hours, TA2 had lower bleeding than
TA1 [978 (95% CI: 809-1147) vs 1198 (95%CI: 1017-1380)
mL; P = 0.010, corrected-P significant], which remained
significant after adjusting for surgery-related bleeding (P =
0.014, corrected-P significant). On summing intraoperative
and 24 h postoperative bleeding, the effect of TA2 was sig-
nificant: [1341 (95% CI: 1197-1486) vs 1538 (95%CI: 1391-
1686) mL; P = 0.016, corrected-P significant]. Also in the
omnibus test, TA2 had significantly lower D-dimer (P =
0.038) than TA1 (Figure 3). TA2 had lower D-dimer levels
at 24 hours [489 (95% CI: 437-540) vs. 621(95% CI: 563-
679) ng/mL; P = 0.01, corrected-P significant].
TA2 showed significant reduction of maximum CPK
values [407(95%CI: 259-671) vs 487(95%CI: 359-812)U/
L; P = 0.01] and TnI [2.6(95%CI: 1.7-4.7) vs 3.6(95%CI:
2.7-6.3)U/L; P > 0.01]. TA2 required lower levels of nor-
epinephrine at 24 h [0.06 (95%CI: 0.03-0.09) vs 0.20
(95CI5%:0.05-0.35), P = 0.03, adjusted for dobutamine
[F(1.40) = 6.6; P = 0.014, corrected-P significant].
No differences were found in hemoderivative require-
ments or other parameters (Table 2).
We found a direct relationship between IL-6 at ICU arri-
val and: temperature (rho = 0.26; P < 0.01), D-dimer (rho
=0 . 2 4 ;P < 0.01), norepinephrine (rho = 0.33; P <0 . 0 1 ) ,
TnI (rho = 0.37; P < 0.01), CK(rho = 0.37; P <0 . 0 1 ) ,C K -
MB(rho = 0.33; P < 0.01) and lactic acid (rho = 0.46; P <
0.01) at arrival. Similarly, a direct correlation was observed
between IL-6 at 4 h with temperature (rho = 0.23; P <
0.01), norepinephrine (rho = 0.25; P <0 . 0 1 ) ,T n I( r h o=
0.42; P < 0.01) and lactic acid (rho = 0.19; P = 0.03) at 4 h
and chest tube bleeding at 24 h (rho = 0.18; P = 0.03) and
at chest-tube withdrawal (rho = 0.20; P = 0.02), and an
inverse relationship with systolic blood pressure at 4 h
(rho = -0.17; P = 0.05).
Seizure was present in 2 (1.3%) and stroke in 3 (1.9%)
patients. Acute kidney injury occurred in 14 (8.8%)
patients, and 7(4.4%) needed dialysis. Finally, 3 (1.9%)
suffered myocardial infarction. Seven patients required
re-operation for bleeding: 5 in TA1 and 2 in TA2,(P=
0.44). There were 9 deaths, without significant differences
between groups: 3 (3.8%) in TA1 versus 6 (7.6%) in TA2
(P = 0.29). Statistically, there were no significant differ-
ences in expected vs. observed mortality between the two
groups. According to logistic Euroscore, the rates of mor-
tality were: TA1-observed = 3.8% (3/80) and TA1-
expected = 3.25% (3/80), (P =0 . 9 9 )a n dT A 2 - o b s e r v e d=
7.6% (6/80)] and TA2-expected = 3.27% (3/80), (P =
0.11). There were no significant differences between
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cardial infarction, mechanical ventilation or ICU stay
after surgery, nor when comparing composite adverse
effects (Table 2).
Discussion
The clinical definition of IR based primarily on early
hyperthermia with a hyperdynamic state is accompanied
by higher levels of IL-6 at 4 h than in other patients.
Peak levels of this interleukin is observed in these first
hours of the postoperative period, as found by our team
in a previous study [6] and by others [16,17]. The pre-
sence of hyperthermia in the criteria used avoids the
potential confounding effect of vasoactive drugs on the
associated hyperdynamic state.
Our findings indicate that prolonged inhibition of
fibrinolysis by a postoperative dose of TA reduces IR
and bleeding in CPB patients. TA1 patients presented
higher levels of D-dimer, greater bleeding and IR than
TA2 patients who received a second dose after CPB.
Several mechanisms have been proposed to explain IR
after CPB, including contact activation, ischemia-reperfu-
sion, and endotoxemia. These triggers may activate numer-
ous systems involving complement, cytokines, immune
cellular response and coagulation-fibrinolytic cascades [4].
These systems are closely interconnected and provide
continuous feedback, so the release of cytokines[18] or
activation of the complement system [19] may amplify the-
fibrinolytic response. This in turn may re-activate the
release of inflammatory mediators by plasmin and
Figure 1 Randomized control trial flow diagram.
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in CPB.
In a previous study, we observed significantly higher
levels of IL-6 in patients with IR and TA was effective in
reducing this response [6]. Thus in the present study we
focused on IL-6 and fibrinolysis. In addition to the feed-
back between the release of inflammatory markers and
fibrinolysis, other components must be considered in the
release of these markers. After CPB (Figure 2) we observed
a clear increase in the levels of IL-6 and other interleukins,
which interact with each other [16,17] and are involved in
producing fever ("postperfusion syndrome”) [22]. Also,
oxidative stress induced by norepinephrine may release
IL-6 in other settings [23]. In this study, we observed no
differences in IL-6 levels between groups, probably
because both them received antifibrinolytic.
Proinflammatory cytokines may contribute to inflamma-
tory response, myocardial ischemia-reperfusión injury and
hemodynamic instability after clinical CPB. This myocar-
dial dysfunction has been highlighted in diverse studies
through the association between cytokine levels (IL-6) and
markers of myocardial tissue damage such as TnI y CK
[24,25]
In the present study, patients developing IR showed
higher levels of IL-6 than those who did not, together
with worse hemodynamic status. The association
between greater cytokine (IL-6) release, activation of
fibrinolysis (D-dimer), higher temperature, higher levels
Table 1 Baseline characteristics of treatment groups
Tranexamic acid P
TA1 group
(40-0 mg/Kg)
(n = 80)
TA2 group
40-40 mg/Kg
(n = 80)
Demographics
Age (years) 65 (62-69) 68 (65-70) 0.24
Male sex, n (%) 54 (67.5) 49 (61.3) 0.41
Parsonnet 9.2 (7.2-11.2) 10.5 (8.4-12.5) 0.30
Euroscore
a 4 (3-6) 4 (3-7) 0.38
Logistic Euroscore
a 3.25(1.83-5.53) 3.27(1.75-6.68) 0.84
Body mass index (Kg/m
2) 28.2 (27.4-29) 27.7 (26.6-28.8) 0.50
Comorbidity
Hypertension, n (%) 43 (53.8) 53 (66.3) 0.11
Diabetes, n (%) 36 (45) 28 (35) 0.42
Medical treatment
Angiotensin-converting enzyme inhibitors, n (%) 28 (35) 22 (27.5) 0.31
Preoperative parameters
Platelet count (× 10
3 ml
-1) 247 (227-267) 262 (239-285) 0.48
D-dimer (ng/ml) 347 (217-476) 287 (221-353) 0.95
International normalized ratio 1.04 (1-1.07) 1.05 (1.01-1.09) 0.28
Cardiac intervention
Coronary, n (%) 45 (56.3) 39 (48.8) 0.51
Valvular, n (%) 25 (31.3) 31 (38.8)
Both, n (%) 9 (11.3) 7 (8.8)
Other, n (%)
b 1 (1.3) 3 (3.8)
Second intervention, n (%) 4 (5) 3 (3.8) 0.51
Surgical data
Temperature during cardiopulmonary bypass (°C) 32.3 (32-32.5) 32.3 (32.1-32.5) 0.78
Aortic clamp time (min) 53 (49-58) 51 (46-57) 0.61
Cardiopulmonary bypass time(min) 88 (82-94) 84 (77-92) 0.45
Temperature after cardiopulmonary bypass (°C) 35.5 (35.3-35.6) 35.7 (35.5-35.8) 0.03
Total heparin dose (UI/Kg) 391 (371-412) 400 (379-421) 0.56
Total protamine dose (mg/Kg) 2.7 (2.6-2.8) 2.9 (2.8-3.1) 0.04
Heparine/protamine 1.45 (1.37-1.53) 1.39 (1.33-1.44) 0.29
Blood salvage (ml) 724 (663-784) 703 (636-767) 0.64
Values expressed as mean and 95% confidence interval; frequencies and percentages;
amedian and percentiles.
bInter-atrial communication.
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instability (norepinephrine requirements and higher lac-
tate levels) in the immediate postoperative period sup-
port the inter-relation between inflammation and
fibrinolysis [18-20].
The protective effect of TA regarding IR, more evident
in the TA2 group, was also reflected in less postopera-
tive myocardial tissue damage.
Optimal use of inotropes or vasopressors in the perio-
perative period of cardiac surgery remains controversial.
Figure 2 Mixed ANOVA showing the relationship between IR and IL-6 during the follow up.
Figure 3 Mixed ANOVA showing the relationship between Tranexamic acid doses and D-Dimer during the follow up.
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norepinephrine in patients who develop postoperative
cardiac dysfunction when there is associated hypoten-
sion, to maintain an adequate perfusion pressure. This
would justify the use of norepinephrine in patients who
do not develop IR [26,27]. Although the initial analysis
revealed no differences in the need for norepinephrine
in the first 24 hours postoperatively between the treat-
ment groups, differences did appear at 24 h after adjust-
ing for the dose of dobutamine at the time.
Although TA effectively reduces bleeding after cardiac
surgery, doses vary widely [12,13]. Most are based on an
Table 2 Outcomes of treatment groups
Tranexamic acid P
TA1 group
(40-0 mg/Kg)
(n = 80)
TA2 group
(40-40 mg/Kg)
(n = 80)
D-dimer (ng/mL) 0-h 363 (307-420) 311 (257-365) 0.038*
D-dimer (ng/mL) 4-h 416 (376-455) 283 (254-312)
D-dimer (ng/mL) 24-h
a 621 (563-679) 489 (437-540)
Chest tube bleeding (cc) 0 h 136 (109-163) 109 (89-129) 0.014†
Chest tube bleeding (cc) 4 h 366 (282-449) 263 (222-304)
Chest tube bleeding (cc) 24 h
b 826 (704-949) 671 (549-793)
Chest tube total bleeding (cc) 1198 (1017-1380) 978 (809-1147)
Transfused patients at 24 h (%) 22 (27.8) 19 (23.8) 0.55
Inflammatory response (%) 15 (18.8) 6 (7.5) 0.03
Temperature > 38 (°C) n(%) 15(18.8) 6(7.5) 0.03
Cardiac index > 3.5 (L/min/m
2) n(%) 65(82.3) 58(75.3) 0.29
Systemic vascular resistance index <1600 (dyne · sec/cm
5 per m
2) n(%) 31(39.2) 21(27.6) 0.13
Interleukine-6 (pg/mL) 0-h 281 (139-423) 239 (177-302) 0.79‡
Interleukine-6 (pg/mL) 4-h 511 (341-679) 470 (327-613)
Creatine kinase (U/L) 0 h 257 (207-352) 208 (160-315) 0.12¶
Creatine kinase (U/L) 4 h 336 (253-460) 281 (228-414)
Creatine kinase (U/L) 24 h 447 (336-807) 399 (266-657)
Creatine kinase peak (U/L) 487 (359-812) 407 (259-671) 0.01
Troponin I (ng/mL) 0 h 1.3 (1-2.8) 1.2 (0.6-1.7) 0.88**
Troponin I (ng/mL) 4 h 3.4 (2.4-5.3) 2.3 (1.6-3.9)
Troponin I (ng/mL) 24 h 1.8 (1.2-3.3) 1.6 (1.1-3.3)
Troponin I peak (ng/mL) 3.6 (2.7-6.3) 2.6 (1.7-4.7) <0.01
Norepinephrine (mcg/Kg/min) 0 h 0.07(0.03-0.12) 0.06(0.02-0.10) 0.46
††
Norepinephrine (mcg/Kg/min) 4 h 0.12(0.04-0.19) 0.09(0.03-0.14)
Norepinephrine (mcg/Kg/min) 24 h 0.20(0.05-0.35) 0.06(0.03-0.09)
Dobutamine (mcg/Kg/min) 0 h 1.77(1.03-2.51) 1.68(0.99-2.38) 0.96
‡‡
Dobutamine (mcg/Kg/min) 4 h 1.60(0.80-2.41) 1.69(0.94-2.44)
Dobutamine (mcg/Kg/min) 24 h 1.19(0.47-1.92) 1.28(0.59-1.98)
Mechanical ventilation (h)
d 7 (5-13) 7 (6-15) 0.60
Re-intervention, n (%) 5 (6.3) 2 (2.5) 0.44
Postoperative stroke, n (%) 1 (1.3) 2 (2.5) 0.56
Seizures, n (%) 0 (0) 2 (2.5) 0.49
Renal dysfunction, n (%) 6 (7.5) 7 (8.9) 0.75
Renal failure, n (%) 4 (5) 3 (3.8) 0.70
Myocardial infarction, n (%) 2 (2.5) 1 (1.3) 0.56
Intensive care length of stay (days)
c 3 (2-5) 3 (2-5) 0.26
Mortality, n (%) 3 (3.8) 6 (7.6) 0.29
Composite Adverse Effects(%) 14(17.5) 11(13.8) 0.51
Values expressed as means and 95% confidence interval; frequencies and percentages.
aD-dimer levels at 24 hours (P = 0.01, corrected P significant).
b Chest bleeding at 24 hours (P = 0.01, corrected P significant).
cNorepinephrine at 24 h adjusted
for dobutamine at 24 h (P = 0.014, corrected P significant).
dValues expressed as median and interquartile range
* †‡¶
** †† ‡‡ P values correspond to omnibus F-scores and were obtained using Mixed ANOVA
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Page 8 of 10initial dose and subsequent infusion, which can result in
high cumulative doses. TA half-life is 80 min, and the
effect of a single dose (TA1) is nearly 100% inhibition of
plasmin activity[14] in the immediate postoperative per-
iod, so a second dose administered at the end of surgery
may prevent IR and bleeding complications, since
enhanced fibrinolysis might be expected after heparin
reversal [28].
Thus the dosing schedule used in our study ensures
complete inhibition of fibrinolysis, although no pharma-
cokinetic information was available. With the second
dose we wished to investigate the possible benefit of
postoperative inhibition of fibrinolysis on IR.
It is questionable whether the statistically smaller
blood loss in TA2 group is really clinically relevant, in
terms of transfusion requirements. The use of hemoder-
ivatives partly depends on the transfusion policy of each
center, as in our case. However, given that numerous
authors concur on the need for antifibrinolytic agents in
cardiac surgery [29], we believe the protective effect of
the TA2 dosing schedule used in the present study on
IR and clinical parameters should be considered.
The incidence of non-ischemic clinical seizure varies
from 2.7% to 4.6% in most major surgical procedures
[ 8 - 1 0 ] ,o n l y0 . 4 %i nC A B G[ 9 ] ,b u ta sh i g ha s6 . 7 %[ 8 ]
or 7.9% [9] in open chamber surgery. This adverse effect
has been reported with different several dosing sche-
dules and cumulative doses of 61-259 mg/kg [8-10].
The incidence of non-ischemic clinical seizure was 0%
in the single-dose group versus 2.5% in the double-dose
group (non-significant difference); one patient under-
went CABG and the other open chamber surgery (valve
replacement), and both had associated renal dysfunction.
Although our incidence was below the limits reported
by other authors, with slightly higher cumulative doses
than those used by Martin K et al [9] and lower than
S a n d e rMe ta l[ 8 ]a n dM u r k i nJ Me ta l[ 1 0 ] ,t h e r e
seems to be a certain dose-dependent relationship with
seizure.
Tranexamic acid has been shown to have an epilepto-
genic effect in animals [30]. The suspected mechanism
is a g-aminobutiric acid-driven inhibition of the central
nervous system [31]. The patho-mechanism of the two
seizures recorded in our study remains undetermined.
Both occurred in patients with postoperative renal dys-
function which facilitates accumulation of the drug, and
one patient underwent aortic valve surgery where
micro-plaque dislodgement or the presence of micobbu-
bles, which inevitably remain after closing the heart,
could have triggered the seizure. This may also partly
explain the higher incidence of seizure in open chamber
surgery
Cerebrovascular events, renal pathology and myocar-
dial infarction were similar to those reported previously
[32]. Hospitalization and mortality were similar in both
groups.
Limitations
With 80 patients in each group, we empirically estimated
a 13% difference between the incidence rates of IR,
because in the balance between safety and effectiveness,
we preferred safety. Although the empirical power for the
observed proportions (18.8 vs. 7.5) was 67%, the study
was sufficiently powered and significant differences were
found at the end of the study.
Although the incidence of adverse events observed are
consistent with that reported in other series, the study
was underpowered to be able to affirm that the dosing
schedule was safe since the sample size was calculated
for IR.
Only IL-6 was measured as a biochemical marker of
inflammatory response to CPB. However, this cytokine
is widely used in this context, as shown in the
literature [16,17].
Blood levels of TA were not measured, but the phar-
macokinetic profile of this drug has been previously stu-
died by other authours and the dosing schedule was
based on their findings [14].
Lastly, the experimental nature of this single-center
study with CPB patients undergoing a particular surgical
technique (with non-coated circuits), limits the external
validity of our findings.
Conclusions
In conclusion, an additional postoperative dose of TA
may reduce IR and postoperative bleeding (but not
transfusion requirements) in CPB patients. A question
which remains unanswered is whether the dose used
was ideal in terms of safety, but in terms of effectiveness
we have no doubt
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